Article -> Article Details

Microbiome therapeutics have drawn significant attention from the medical community with their potential to address the existing unmet need of various clinical conditions. The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032.

The existing  microbiome therapeutics market  is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market.

Impact of COVID-19

There were numerous consequences due to the COVID-19 pandemic, especially because of the reduced access to care for other illnesses. As the number of individuals becoming ill from COVID-19 kept increasing and for the protection of healthy individuals from being affected by the disease, all non-urgent healthcare facilities were suspended as per respective government directives. Even though these measures were necessary, it had mostly negative impact on the Global microbiome therapeutics market. Some the major impacts were; interruption of key clinical trial activities, modification of clinical trial guidelines bringing in additional safety measures, and delay in regulatory agencies' review and approval timeline.

Market Segmentation:

Within the research report, the market is segmented on the basis of:

• target therapy area (gastrointestinal and infectious diseases, skin disorders, cancer indications, and other indications)
• region (North America, Europe, Asia-Pacific, and Rest-of-the-World).

This segmentation highlights value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, and future opportunities, among others, to detail the scope and provide a 360-coverage of the domain.

Segmentation 1: by Target Therapy Area

Disorders related to gastrointestinal (GI) and skin disorders command a major share of the microbiome therapeutics segment, and is expected to continue during the forecast period. Most of the microbiome therapeutics in advanced development stage are indicated to treat C.diff. infection (CDI) and expected to enter the market first. The selected indications were on the basis of research intensity in the specific therapy area. 

Segmentation 2: by Region

Asia-Pacific (APAC) is expected to dominate the global microbiome therapeutics market for the forecast period 2022-2032 continuing with it overall contribution of approximately 40% of the total market size in 2021 followed by Europe with 32.59%. Increasing healthcare expenditure, coupled with government initiatives, are among the leading factors contributing to the growth of the market.

Demand – Drivers and Challenges

Some of the potential drivers identified by BIS Research include:

• Growing Strategic Activities in Microbiome Therapeutics Segment
• Potential of Microbiome Therapeutics to Address Unmet Needs of Existing Treatment Options
• Microbiome Therapeutic Products as a Safer Alternative to Conventional Drug Treatments

There are some challenges identified for the global microbiome therapeutics market are; Lack of standard regulatory guidelines and safety issues associated with live biotherapeutic products (LBPs).

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

The top segment players leading the market include Sanofi SA and Taisho Pharmaceutical Holding that capture around 88% of the market with Sanofi SA holding 64.31% while Taisho Pharmaceutical Holdings 24.49% respectively. 

Some of the prominent established names in this market are:

• 4D pharma plc
• Seres Therapeutics, Inc.
• Microbiotics
• Enterome
• Enterome Biosciences
• Destiny Pharma plc
• Taisho Pharmaceutical Holdings
• AOBiome Therapeutics, Inc.
• Finch Therapeutics Group, Inc.
• Rebiotix Inc. (A Subsidiary of Ferring Pharmaceuticals)
• MaaT Pharma
• Vedanta Biosciences Inc.
• OxThera AB
• Pendulum Therapeutics
• Caelus Health
• Quorum Innovations
• Sanofi SA
• DermBiont, Inc.
• EnteroBiotix Ltd
• YSOPIA Bioscience
• Winclove Probiotics
• TargEDys
• Evelo Biosciences, Inc.
• BiomX
• Biomica Ltd.
• Scioto Biosciences, Inc.
• Lactobio A/S

Key Questions Answered in the Report

• What are microbiome therapeutics products?
• How has microbiome therapeutics evolved over the years since its inception?
• What are the major market drivers, challenges, and opportunities in the global microbiome therapeutics market?
• What are the potential indications targeted using microbiome therapeutics products?
• What does the pipeline for the microbiome therapeutics products market look like?
• What is the market size and future potential of microbiome therapeutics products?
• How does the clinical trial landscape look for the global microbiome therapeutics products market?
• What was the impact of COVID-19 on this market?
• Which region is expected to contribute the highest revenue to the global microbiome therapeutics products market during the forecast period?
• What are the key development strategies implemented by the major players in order to sustain them in the competitive market?
• How is each segment of the market expected to grow during the forecast period 2022-2032? Following are the segments
• Target Therapy Area (gastrointestinal and infectious diseases, skin disorders, cancer indications, and other indications)
• Region (North America, Europe, Asia-Pacific (APAC), Rest-of-the-World)
• What are the existing partnership landscape and regulations for microbiome therapeutics?

Get Free Sample Report - https://bisresearch.com/requestsample?id=1326type=download

BIS Related Studies

Cancer Microbiome Sequencing Market - A Global and Regional Analysis

Global Skin Microbiome Modulators Market

Global Human Microbiome Modulators Market – Analysis and Forecast, 2018-2023